DeepMed Research

ALEXION PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1992-01-01

Employees: 3.8K

Market Cap: -

Website: http://www.alexion.com

Clinical Trials

US Selumetinib Registry

Terminated

Conditions: Plexiform Neurofibromas
Neurofibromatosis Type 1

First Posted Date: 2023-01-13

Last Posted Date: 2025-04-04

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 37

Registration Number: NCT05683678

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States

and more 7 locations

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis
gMG

Interventions: Drug: Ravulizumab

First Posted Date: 2022-12-09

Last Posted Date: 2025-04-25

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT05644561

Locations: 🇨🇭
Research Site, Bern, Switzerland

Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants

Phase 1

Completed

Conditions: Wilson Disease

Interventions: Drug: ALXN1840

First Posted Date: 2022-12-07

Last Posted Date: 2023-11-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT05641311

Locations: 🇬🇧
Richmond Pharmacology Ltd., St George's University of London, London, United Kingdom

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Adult Participants

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C

First Posted Date: 2022-10-13

Last Posted Date: 2025-02-14

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 42

Registration Number: NCT05578846

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

Phase 2

Terminated

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: ALXN1820

First Posted Date: 2022-10-04

Last Posted Date: 2025-01-13

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 2

Registration Number: NCT05565092

Locations: 🇺🇸
Research Site, Indianapolis, Indiana, United States

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Phase 3

Active, not recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Combination Product: ALXN1720
Combination Product: Placebo

First Posted Date: 2022-09-27

Last Posted Date: 2025-05-11

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 260

Registration Number: NCT05556096

Locations: 🇬🇧
Research Site, Sheffield, United Kingdom

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: ALXN2030
Drug: Placebo

First Posted Date: 2022-08-15

Last Posted Date: 2025-05-09

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT05501717

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALXN2080
Drug: Placebo

First Posted Date: 2022-06-23

Last Posted Date: 2024-06-07

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 90

Registration Number: NCT05428696

Locations: 🇬🇧
Clinical Trial Site, Belfast, United Kingdom

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ravulizumab
Drug: rHuPH20

First Posted Date: 2022-05-31

Last Posted Date: 2024-01-22

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 49

Registration Number: NCT05396742

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Phase 3

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Danicopan

First Posted Date: 2022-05-25

Last Posted Date: 2025-04-06

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 80

Registration Number: NCT05389449

Locations: 🇬🇧
Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy